Artificial intelligence (AI) is poised to revolutionize the pharmaceutical industry, offering unprecedented opportunities in drug discovery, clinical trials, and patient care. However, this potentially rapid transformation presents significant challenges and risks. This report, the second in our series on AI in healthcare, provides pharmaceutical leaders with a comprehensive analysis of six very real dilemmas associated with AI adoption – ethical considerations (privacy & confidentiality, and bias & fairness), operational factors (safety, transparency, and explainability), and human factors (autonomy & decision-making, and training).
We explore each dilemma in depth, offering industry-specific examples, risk assessments, and practical mitigation strategies.
While AI presents formidable challenges, we firmly believe that proactive management and strategic implementation can significantly mitigate risks. The paper concludes with three recommendations for pharmaceutical leaders and decision-makers to help navigate the AI landscape responsibly and effectively.
Lumanity stands at the forefront in the use and integration of AI across the commercialization lifecycle. Our teams
provide expertise to companies looking to leverage the full AI potential, with a clear and informed strategy to consider and
mitigate associated risks, and rapidly gain real value from AI.
